Piramal Pharma (NSE:PPLPHARMA) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma ROE % Adjusted to Book Value?

Piramal Pharma's ROE % for the quarter that ended in Dec. 2024 was 0.19%. Piramal Pharma's PB Ratio for the quarter that ended in Dec. 2024 was N/A. Piramal Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.

Piramal Pharma ROE % Adjusted to Book Value Historical Data

The historical data trend for Piramal Pharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma ROE % Adjusted to Book Value Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

ROE % Adjusted to Book Value

-2.31

0.11

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial										-	2.38	-	0.30	-

Competitive Comparison of Piramal Pharma's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Piramal Pharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Piramal Pharma's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Piramal Pharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Piramal Pharma's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Piramal Pharma ROE % Adjusted to Book Value Calculation

Piramal Pharma's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.24%	/	2.15
	=	0.11%

Piramal Pharma's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.19%	/	N/A
	=	N/A

Piramal Pharma ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » ROE % Adjusted to Book Value

Traded in Other Exchanges

543635:India

Address

Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramal.com

Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.

Piramal Pharma Headlines

No Headlines